Search
for
Sort by
Research 151–180 of 1000+
- In Silico Structure-Based Drug Design Approach To Evaluate Quercetin And Kaempferol As Dual Inhibitors Of Jak3 Kinase And 5-Alpha Reductase Type II with ADMET Profiling
- Treatment of male rats with finasteride, an inhibitor of 5alpha-reductase enzyme, induces long-lasting effects on depressive-like behavior, hippocampal neurogenesis, neuroinflammation and gut microbiota composition
- The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles.
- Finasteride, a 5alpha-reductase inhibitor, potentiates antinociceptive effects of morphine, prevents the development of morphine tolerance and attenuates abstinence behavior in the rat
- Finasteride, a 5alpha-reductase enzyme inhibitor, alone and synergism with a neurosteroid reduces responsiveness to nociceptive stimuli in male rat
- Evaluation of New Pregnane Derivatives as 5.ALPHA.-Reductase Inhibitor.
- Finasteride and the 5-Alpha Reductase Inhibitors
- 0192 Estrogenic effects of 5-alpha-reductase inhibitors in male androgenetic alopecia patients
- Finasteride: the first 5 alpha-reductase inhibitor.
- Finasteride: a 5 alpha-reductase inhibitor.
- Abietic Acid from Resina Pini of Pinus Species as a Testosterone 5.ALPHA.-Reductase Inhibitor
- Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men.
- Relative efficacy of minoxidil and 5-alpha-reductase inhibitors in the treatment of male androgenetic alopecia: protocol for a network meta-analysis study
- Review of the Efficacy of Topical 5-Alpha Reductase Inhibitors for the Treatment of Androgenetic Alopecia
- Re: A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Post-Finasteride Syndrome
- Studies on Neurosteroids XXV. Influence of a 5.ALPHA.-Reductase Inhibitor, Finasteride, on Rat Brain Neurosteroid Levels and Metabolism
- Clinical and hormonal effects of the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism
- Risk of estrogen-driven malignancies in females on 5-alpha reductase inhibitors
- Benign Prostatic Hyperplasia Pharmacotherapy and Incident Ocular Surface Disease: Comparative Risk of Alpha-Blockers vs 5-Alpha Reductase Inhibitors
- Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
- Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
- Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
- Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
- Effect of finasteride, a 5 alpha-reductase inhibitor, on serum gonadotropins in normal men
- The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness
- Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men
- Quality-of-life changes in women with female androgenetic alopecia treated with a methylsulfonylmethane-containing 5-alpha-reductase inhibitor: a clinical practice study
- DIHYDROTESTOSTERONE AND THE PROSTATE: THE SCIENTIFIC RATIONALE FOR 5α-REDUCTASE INHIBITORS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
- The Risks and Benefits of 5α-Reductase Inhibitors for Prostate-Cancer Prevention
- Association of Suicidality and Depression With 5α-Reductase Inhibitors